Johnson & Johnson reported second-quarter 2026 sales of $25.31 billion, up 6.6% year over year, with Innovative Medicine sales of $16.384 billion, up 7.8% — per the earnings release filed with the SEC on July 15, 2026. The company raised full-year guidance to reported sales of $101.1 billion and adjusted EPS of $11.68 at the midpoints.
What did the quarter actually show?
The filing's headline figures: reported sales of $25,310 million against $23,743 million a year earlier, a 6.6% increase; net earnings of $5,534 million, down 0.1%; diluted EPS of $2.27, down 0.9%; and adjusted net earnings of $7,081 million, up 5.7%, for adjusted diluted EPS of $2.90 versus $2.77. The company also cited free cash flow of approximately $8.7 billion against $6.2 billion in the prior-year period.
Segments diverged. Innovative Medicine grew reported sales 7.8% to $16,384 million; MedTech grew 4.5% to $8,926 million, per the segment table in the filing. CNBC, citing the quarter, reported that the pharmaceutical unit's growth was driven by Tremfya, which jumped 72.5% to $2 billion, and Darzalex at $4.2 billion in quarterly revenue.
The quarter's regulatory highlights, per the release, include approvals of Tremfya to inhibit the progression of structural joint damage in adults with active psoriatic arthritis, Caplyta for the prevention of relapse in schizophrenia, and the Dual Energy ThermoCool SmartTouch SF mapping catheter platform — a spread across immunology, neuroscience, and devices that matches the two-segment structure.
Why does the guidance raise matter?
The raise converts a strong quarter into a full-year claim: with quarterly sales surpassing $25 billion, CEO Joaquin Duato said in the release that the company is "on track to meet our 2026 target of more than $100 billion in annual revenue for the first time in our Company's 140-year history." The new midpoint of $101.1 billion in reported sales, company-claimed, and the $0.13 adjusted EPS increase to $11.68 anchor that trajectory.
For the industry reader, the number to watch is the composition. The 7.8% reported growth in Innovative Medicine carried the quarter, while MedTech's 4.5% was the slower engine; CNBC reported that the MedTech performance overshadowed the overall beat among analysts focused on that unit. Pipeline items named in the release — Rybrevant Fasco in advanced head and neck cancer, Talvey plus Darzalex Fasco in earlier-line multiple myeloma, and the Ottava surgical robot in upper abdominal procedures — indicate where the company is placing the next leg of growth in both segments.
The comparison with the prior year frames the scale of the upgrade: a year earlier the company posted $23.7 billion in quarterly sales and adjusted EPS of $2.77. What the second half of 2026 holds beyond the raised midpoint — including the pace of the planned Orthopaedics separation referenced in the quarter's materials — is a question for the next report, with the quarter's earnings release as the baseline document.
This article is for informational purposes only and does not constitute investment or medical advice.
